While anti-PD-1 therapy alone did not restrict tumor growth or prolong survival (Fig. 4D, E), the combination of Suv420h1 KO and anti-PD-1 therapy significantly restricted tumor growth (p<0.001) and prolonged survival (Log-rank, p=0.005) compared to anti-PD-1 therapy or Suv420h1 KO alone (Fig. 4D, E). The gene discussed is KMT5B; the disease is neoplasm.